Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival (rPFS) vs. change in ARPI in Phase III PSMAfore trial* ...

--Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American ...

Pluvicto is expected to be available to physicians and patients within weeks. The FDA has also approved Locametz ® (kit for the preparation of gallium Ga 68 gozetotide injection) 2 .

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

After adjusting for crossover, Pluvicto showed a 20% reduction in the risk of death. The reported data included 45% of deaths that will trigger a final overall survival (OS) analysis.

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

New report finds colorectal cancer rising among U.S. adults under 55 04:17. Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported ...

“Pluvicto is a radiation treatment, but not with a beam, it’s given with an IV into the body, and it’s a very sophisticated concept,” said Dr. Gary Kirsh, a urologist at The Urology Group.

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...